The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD)

被引:4
作者
Li, Shu-Jing [1 ]
Liu, An-Bu [2 ]
Yu, Yuan-Yuan [2 ]
Ma, Jin-Hai [1 ]
机构
[1] Ningxia Med Univ, Gen Hosp, Dept Pediat Med, Yinchuan, Ningxia, Peoples R China
[2] Ningxia Med Univ, Gen Hosp, Dept Emergency Med, Yinchuan, Ningxia, Peoples R China
关键词
non-alcoholic fatty liver disease (NAFLD); pyroptosis; NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome; gasdermin D (GSDMD); caspase; targeted therapy; NLRP3 INFLAMMASOME ACTIVATION; HEPATOCYTE PYROPTOSIS; HEPATIC STEATOSIS; CELL-DEATH; FIBROSIS; STEATOHEPATITIS; NASH; INHIBITOR; APOPTOSIS; LIPOTOXICITY;
D O I
10.3389/fcell.2024.1407738
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is a clinical pathological syndrome characterized by the excessive accumulation of fat within liver cells, which can progress to end-stage liver disease in severe cases, posing a threat to life. Pyroptosis is a distinct, pro-inflammatory form of cell death, differing from traditional apoptosis. In recent years, there has been growing research interest in the association between pyroptosis and NAFLD, encompassing the mechanisms and functions of pyroptosis in the progression of NAFLD, as well as potential therapeutic targets. Controlled pyroptosis can activate immune cells, eliciting host immune responses to shield the body from harm. However, undue activation of pyroptosis may worsen inflammatory responses, induce cellular or tissue damage, disrupt immune responses, and potentially impact liver function. This review elucidates the involvement of pyroptosis and key molecular players, including NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome, gasdermin D (GSDMD), and the caspase family, in the pathogenesis and progression of NAFLD. It emphasizes the promising prospects of targeting pyroptosis as a therapeutic approach for NAFLD and offers valuable insights into future directions in the field of NAFLD treatment.
引用
收藏
页数:14
相关论文
共 50 条
[41]   PEDIATRIC NON-ALCOHOLIC FATTY LIVER DISEASE [J].
Delvin, Edgard ;
Patey, Natasha ;
Dubois, Josee ;
Henderson, Melanie ;
Levy, Emile .
JOURNAL OF MEDICAL BIOCHEMISTRY, 2015, 34 (01) :3-12
[42]   Histopathology of Non-Alcoholic Fatty Liver Disease [J].
Brunt, Elizabeth M. .
CLINICS IN LIVER DISEASE, 2009, 13 (04) :533-+
[43]   Paediatric non-alcoholic fatty liver disease [J].
Nobili, Valerio ;
Pinzani, Massimo .
GUT, 2010, 59 (05) :561-564
[44]   Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy [J].
Yao, Pengyu ;
Liu, Yajuan .
MOLECULES, 2023, 28 (01)
[45]   Lipidomics in non-alcoholic fatty liver disease [J].
Kartsoli, Sofia ;
Kostara, Christina E. ;
Tsimihodimos, Vasilis ;
Bairaktari, Eleni T. ;
Christodoulou, Dimitrios K. .
WORLD JOURNAL OF HEPATOLOGY, 2020, 12 (08) :436-450
[46]   Predictors of non-alcoholic fatty liver disease (NAFLD) among children with obesity [J].
Mohamed, Rashdan Zaki ;
Jalaludin, Muhammad Yazid ;
Zaini, Azriyanti Anuar .
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2020, 33 (02) :247-253
[47]   Curative role of natural PPARγ agonist in non-alcoholic fatty liver disease (NAFLD) [J].
Singh, Swati ;
Kumar, Anit ;
Gupta, Suruchi ;
Agrawal, Rohini .
TISSUE BARRIERS, 2024, 12 (03)
[48]   What's New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) [J].
Kosmalski, Marcin ;
Frankowski, Rafal ;
Ziolkowska, Sylwia ;
Rozycka-Kosmalska, Monika ;
Pietras, Tadeusz .
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (05)
[49]   The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease [J].
Xu, Hao ;
Wang, Lin .
FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 8
[50]   Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease [J].
Lee, Jin ;
Park, Jeong-Su ;
Roh, Yoon Seok .
ARCHIVES OF PHARMACAL RESEARCH, 2019, 42 (11) :935-946